{"public_id":"co_8b9a7ec628ffffcaae9804078935bb2b","status":"active","merged_into_public_id":null,"resolved_public_id":"co_8b9a7ec628ffffcaae9804078935bb2b","name":"Janus kinase inhibitors","description":"Drugs that inhibit Janus kinase signaling pathways.","aliases":["JAK inhibitors"],"types":["drug class"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":275406579,"title":"Axial spondyloarthritis.","citation_count":26,"url":"https://sah.borca.ai/papers/275406579"}],"claims":[{"public_id":"cl_d3cc3153d55760aabc79d67c4bf5daa1","text":"Non-steroidal anti-inflammatory drugs remain first-line pharmacotherapy, while tumour necrosis factor, IL-17, and Janus kinase inhibitors are considered second-line therapies.","corpus_id":275406579,"url":"https://sah.borca.ai/claims/cl_d3cc3153d55760aabc79d67c4bf5daa1"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_8b9a7ec628ffffcaae9804078935bb2b","url":"https://sah.borca.ai/concepts/co_8b9a7ec628ffffcaae9804078935bb2b"}